These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 8638026)

  • 61. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [Anti-arrhythmia agents in the therapy of ventricular arrhythmias in the post-CAST era].
    Candinas R; Bauersfeld U
    Schweiz Med Wochenschr; 1994 Sep; 124(35):1545-9. PubMed ID: 7939521
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antiarrhythmic drugs versus implantable defibrillators: the need for a randomized controlled study.
    Greene HL
    Am Heart J; 1994 Apr; 127(4 Pt 2):1171-8. PubMed ID: 8160597
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Class III drugs and congestive heart failure: focus on the congestive heart failure-survival trial of antiarrhythmic therapy.
    Singh SN; Fletcher RD
    Am J Cardiol; 1999 Nov; 84(9A):103R-108R. PubMed ID: 10568668
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
    Giorgberidze I; Saksena S; Krol RB; Munsif AN; Kolettis T; Mathew P; Varanasi S; Prakash A; Delfaut P; Lewis CB
    Am J Cardiol; 1997 Sep; 80(5B):3F-9F. PubMed ID: 9291444
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Long-term efficacy of d/l sotalol in patients with sustained ventricular tachycardia refractory to class I antiarrhythmic drugs.
    Kühlkamp V; Mermi J; Mewis C; Braun U; Seipel L
    Eur Heart J; 1995 Nov; 16(11):1625-31. PubMed ID: 8881857
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Sotalol for cardiac arrhythmias.
    Med Lett Drugs Ther; 1993 Apr; 35(893):27-8. PubMed ID: 8450806
    [No Abstract]   [Full Text] [Related]  

  • 68. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators.
    Mason JW
    N Engl J Med; 1993 Aug; 329(7):452-8. PubMed ID: 8332150
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Role of determination of QT dispersal intervals in anti-arrhythmia therapy].
    Konecná P; Dvorák R; Semrád B
    Vnitr Lek; 1999 Aug; 45(8):453-6. PubMed ID: 11045143
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prevention of implantable-defibrillator shocks by treatment with sotalol. d,l-Sotalol Implantable Cardioverter-Defibrillator Study Group.
    Pacifico A; Hohnloser SH; Williams JH; Tao B; Saksena S; Henry PD; Prystowsky EN
    N Engl J Med; 1999 Jun; 340(24):1855-62. PubMed ID: 10369848
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Indications and limitations of class II and III antiarrhythmic drugs in atrial fibrillation.
    Hohnloser SH
    Pacing Clin Electrophysiol; 1994 May; 17(5 Pt 2):1019-25. PubMed ID: 7518589
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Long-term results of electrophysiologically guided sotalol therapy for life-threatening ventricular arrhythmias.
    Lee RJ; Wong M; Siu A; Namekawa-Wong M; Epstein LM; Fitzpatrick AP; Grogin HR; Scheinman MM; Lesh MD
    Am Heart J; 1996 Nov; 132(5):973-8. PubMed ID: 8892770
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Potential proarrhythmic effect of biventricular pacing: fact or myth?
    Shukla G; Chaudhry GM; Orlov M; Hoffmeister P; Haffajee C
    Heart Rhythm; 2005 Sep; 2(9):951-6. PubMed ID: 16171749
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
    Kühlkamp V; Mermi J; Mewis C; Seipel L
    J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Long-term follow-up of patients requiring intravenous amiodarone to suppress hemodynamically destabilizing ventricular arrhythmias.
    Fogel RI; Herre JM; Kopelman HA; Kowey PR; Trohman RG; Fineberg N; Prystowsky EN
    Am Heart J; 2000 Apr; 139(4):690-5. PubMed ID: 10740153
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Design and analysis of the ESVEM Trial.
    Anderson KP; Hartz VL; Hahn EA; Moon TE
    Prog Cardiovasc Dis; 1996; 38(6):489-502. PubMed ID: 8638029
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Comparison of the long-term efficacy of implantable defibrillators and sotalol for documented spontaneous sustained ventricular tachyarrhythmias secondary to coronary artery disease.
    Kovoor P; Yung A; Byth K; Eipper VE; Uther JB; Cooper MJ; Ross DL
    Aust N Z J Med; 1999 Jun; 29(3):331-41. PubMed ID: 10868496
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Predictability of response rates, efficacy, risks, and intolerance with sotalol when used for sustained ventricular arrhythmias.
    Reiffel JA
    Am Heart J; 1999 Feb; 137(2):372-3. PubMed ID: 10049191
    [No Abstract]   [Full Text] [Related]  

  • 80. Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia.
    Wichter T; Borggrefe M; Haverkamp W; Chen X; Breithardt G
    Circulation; 1992 Jul; 86(1):29-37. PubMed ID: 1617780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.